Inventor · disambiguated record
Ophelia Yin
Also filed as: YIN OPHELIA · YIN OPHELIA QIPING
1 granted patent·8 pending applications·18 citations·filing 2010–2022
37Inventor score
Files withSZCZUDLO TOMASZ3AGIOS PHARMACEUTICALS INC2DAIICHI SANKYO CO LTD2GALLAGHER NEIL1NOVARTIS AG1
Top patents by PatentIndex Score
9 records- 0178US9061029B2Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activityGALLAGHER NEIL·Filed 2010·Granted Jun 23, 2015·18 cites·8 claims
- 0253US2025108049A1Compounds for treating mds-associated anemias and other conditionsAGIOS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0351US2022036993A1Pexidartinib risk evaluation and mitigation strategy (rems)DAIICHI SANKYO CO LTD·Filed 2021·Application pending·0 cites
- 0451US2022034871A1Methods for administering pexidartinibDAIICHI SANKYO CO LTD·Filed 2021·Application pending·0 cites
- 0548US2014350037A1Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activitySZCZUDLO TOMASZ·Filed 2014·Application pending·0 cites
- 0647US2023338283A1Pharmaceutical formulationAGIOS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0746US2017143716A1Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activityNOVARTIS AG·Filed 2017·Application pending·0 cites
- 0840US2012202836A1Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activitySZCZUDLO TOMASZ·Filed 2010·Application pending·0 cites
- 0938US2015313900A1Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activitySZCZUDLO TOMASZ·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ophelia Yin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →